Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 26:10:2163-2169.
doi: 10.2147/PPA.S102234. eCollection 2016.

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder

Jonathan Greenberg  1 , Jacqueline B Palmer  2 , Wing W Chan  2 , Catherine E Correia  1 , Diane Whalley  3 , Paul Shannon  3 , Gregory S Sawicki  1
Affiliations

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder

Jonathan Greenberg et al. Patient Prefer Adherence. .

Abstract

Background: This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder-inhaled antibiotic for Pseudomonas aeruginosa infection.

Methods: CF patients aged 6 years or older treated with at least one cycle of TIP completed a web survey on experience with TIP, including the Treatment Satisfaction Questionnaire for Medication (TSQM). Regression analysis determined the factors associated with TSQM global satisfaction.

Results: Eighty patients (mean age ± standard deviation: 24.4±9.4 years; 57.5% female; mean forced expiratory volume in 1 second ± standard deviation: 67.1%±27.3% predicted) completed the survey. The majority expressed satisfaction with TIP's administration time (100%), time to clean (97.1%), portability (97.1%), and ease of use (94.3%). Effectiveness was significantly associated with TSQM global satisfaction (regression R-squared: 0.54).

Conclusion: Patient preferences for TIP were based on administration time and ease of use. Global satisfaction was related to greater patient-perceived effectiveness.

Keywords: cystic fibrosis; dry powder inhalers; patient satisfaction; tobramycin.

PubMed Disclaimer

Conflict of interest statement

JBP and WWC are employees of Novartis Pharmaceuticals. DW and PS are employees of RTI Health Solutions. RTI Health Solutions and Boston Children’s Hospital each received funding from Novartis Pharmaceuticals for this study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of patient participation. Abbreviations: CFQ-R, Cystic Fibrosis Questionnaire-Revised; TIP, tobramycin inhalation powder; TSQM, Treatment Satisfaction Questionnaire for Medication.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Collaco J, McGready J, Green DM, et al. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One. 2011;6(11):e27784. - PMC - PubMed
    1. Edelstein MV, Skleenova EN, Shevchenko OV, et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis. 2013;13(10):867–876. - PubMed
    1. Davies JC. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. Paediatr Respir Rev. 2002;3(2):128–134. - PubMed
    1. Mogayzel PJ, Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med. 2013;187(7):680–689. - PubMed
    1. Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11(6):461–479. - PubMed

LinkOut - more resources